New England Accountable Care Group Selects Gold Standard Drug Database
TAMPA, Florida, November 5, 2012
TAMPA, Florida, November 5, 2012 /PRNewswire/ --
Elsevier's Gold Standard will provide NNEACC with essential drug information
in a streamlined database solution
Elsevier's Gold Standard , a leading drug information provider, announced
today that the Northern New England Accountable Care Collaborative , LLC
(NNEACC), composed of Eastern Maine Healthcare Systems, Dartmouth-Hitchcock
Health, MaineHealth and Dartmouth College, has selected the Gold Standard Drug
Database to deliver current and accurate drug data and drug decision support.
The integration of the Gold Standard Drug Database module will allow the
NNEACC to streamline and automate the process of integrating prescribing data
with administrative and clinical information to provide a robust view of
patient activity to clinicians.
The Gold Standard Drug Database will offer NNEACC drug pricing updates,
therapeutic groupings of drug products, brand versus generic identifiers, and
accurate information on generics. The Gold Standard Drug Database interacts
intelligently with patient-prescribing data to guide the clinician to an
efficient and effective delivery of the patient's medication, assisting
adherence to drug therapy for best health benefits. NNEACC will benefit from
the database's modern technical architecture, combined with current, accurate
content and built-in human logic for superior decision support, which
distinguishes Gold Standard Drug Database from other drug compendia.
"The Gold Standard Drug Database will significantly enhance the way we receive
and interpret drug information, administration and pricing," said Dr. David
Wennberg, CEO of NNEACC. "This database will give us access to the most
current and accurate drug data and decision support."
NNEACC was co-founded by Dartmouth-Hitchcock Health, Eastern Maine Healthcare
Systems, MaineHealth and Dartmouth College to develop, implement and evaluate
new models of clinical care required to achieve the triple aim of improved
population health, improved quality and satisfaction of the patient experience
and reduced per capita costs. Led by Dr. David Wennberg, the NNEACC solution
integrates administrative and clinical data sources in a proven data
technology foundation with innovative analytics to provide focused and
actionable information that supports clinicians and administrators as they
"We look forward to providing NNEACC with the critical information needed to
streamline drug information and improve the efficiency of daily processes,"
said Marianne Messer, President of Elsevier's Gold Standard. "Our innovative
clinical decision support solutions enable us to provide drug information
rapidly and effectively to ensure that the NNEACC will have the latest and
best information, ultimately assisting in better care."
For more information about NNEACC, please visit http://www.nneacc.com .
For more information about Elsevier's Gold Standard, please visit
Elsevier's Gold Standard
Based in Tampa, FL, Elsevier's Gold Standard uses innovative technologies to
provide a complete suite of drug information and decision support solutions.
With a tenacious commitment to product quality, Elsevier's Gold Standard
solutions empower healthcare organizations, professionals and consumers to
meet the most pressing healthcare challenges, improve patient safety and
ensure optimal outcomes. To learn more about Elsevier's Gold Standard, visit
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Nursing
Suite , which enhance the productivity of science and health professionals,
and the SciVal suite and MEDai's Pinpoint Review , which help research and
healthcare institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL
(London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Christopher Capot Director, Corporate Relations, Elsevier
Press spacebar to pause and continue. Press esc to stop.